Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Glofitamab After CAR T-cell Therapy in Relapsed/Refractory Lymphomas
2020-001985-12Phase 2Active
- Sponsor
- LYSARC
- Start
- Dec 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and 2 more (2 cohorts), sponsored by LYSARC. Primary endpoint: Overall survival. Started Dec 2020; status: active.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)indolent lymphomaTransformed Indolent Non-Hodgkin Lymphoma
Beyond the preview
Go deeper on 2020-001985-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001985-12.